Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 3 2

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Gynecologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 8Breast Neoplasms 7Urinary Bladder Neoplasms 4Carcinoma, Transitional Cell 4Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Prostatic Neoplasms, Castration-Resistant 1Pancreatic Neoplasms 1Meningeal Carcinomatosis 1HRD Cancer 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Breast Cancer 1

Interventions

pembrolizumab 26Nivolumab 10Cisplatin 9Gemcitabine 8Docetaxel 6enfortumab vedotin 5atezolizumab 5Ipilimumab 5Carboplatin 5sacituzumab govitecan 4Paclitaxel 4Pemetrexed 3Cyclophosphamide 3vofatamab 2tremelimumab 2tislelizumab 2regorafenib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2Bevacizumab 2B701 protein, Human herpesvirus 6 2ALT-803 2yeast-CEA vaccine 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Transitional Cell × sacituzumab govitecan × Clear all
NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Hoffmann-La Roche

Phase 1/2 Completed
272 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04863885 2025-12-17

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
46 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04724018 2025-11-04

Sacituzumab Govitecan Plus EV in Metastatic UC

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
106 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03992131 2024-01-16

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

pharmaand GmbH

Phase 1/2 Terminated
25 enrolled 11 charts
BreastGenitourinaryGynecologic

Carcinoma, Transitional Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡